Funded Projects › H2020
MATURE-NK · MAnufacturing of TUmour-REactive Natural Killer cells
This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products (""ATMPs""), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine.In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors (""CAR"") and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors (""checkpoint inhibitors"") and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials. ""
Consortium · 14 organisations
MEDIZINISCHE HOCHSCHULE HANNOVER
DE · €249,216
UNIVERSIDAD POMPEU FABRA
ES · €247,873
MEDIZINISCHE UNIVERSITAET WIEN
AT · €255,934
MILTENYI BIOTEC BV & CO KG
DE · €186,912
GLYCOSTEM-THERAPEUTICS B.V.
NL · €255,374
UNIVERSITAT BASEL
CH · €265,227
INNATE PHARMA
FR · €182,553
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
DE · €325,366
MILTENYI BIOTEC GMBH
DE · €62,304
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
DE · €249,216
OSLO UNIVERSITETSSYKEHUS HF
NO · €286,275
INSTITUT PASTEUR
FR · €262,876
IRCCS AZIENDA OSPEDALIERA METROPOLITANA
IT · €258,061
THE HEBREW UNIVERSITY OF JERUSALEM
IL · €260,301
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.